Chemoprevention of prostate cancer

Annual Review of Medicine

Volumn 57, Issue , 2006, Pages 49-63

  Klein, Eric A ^a  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

Finasteride; Selenium; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; CYCLOOXYGENASE 2 INHIBITOR; DUTASTERIDE; FINASTERIDE; GREEN TEA EXTRACT; LYCOPENE; NONSTEROID ANTIINFLAMMATORY AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SELENIUM; VITAMIN D;

CANCER PREVENTION; DIET SUPPLEMENTATION; DRUG MECHANISM; GLEASON SCORE; HUMAN; NUTRITION; PRECANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOYBEAN;

ANTIOXIDANTS; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; ISOFLAVONES; MALE; PROSTATIC NEOPLASMS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 32944481144     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.57.121304.131435     Document Type: Review

References (53)

1. Lieberman R, Kagan J, House MG, et al. 2004. Strategies for the chemoprevention of cancer. In Management of Prostate Cancer, ed. EA Klein, pp. 71-106. Totowa, NJ: Humana. 2nd ed.
2. American Cancer Society. 2004. Cancer Facts & Figures 2005. http://www.cancer. org
3. Stanford JL, Feng Z, Hamilton AS, et al. 2000. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 283:354-60
4. Potosky AL, Legler J, Albertsen PC, et al. 2000. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J. Natl. Cancer Inst. 92:1582-92
5. Hoffman RM, Gilliland FD, Penson DF, et al. 2004. Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls. Cancer 101:2011-19
6. Landis SH, Murray T, Bolden S, et al. 1999. Cancer statistics 1999. CA Cancer J. Clin. 49:8-31
7. Smith JR, Freije D, Carpten JD, et al. 1995. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274:1371-74
8. Carter BS, Bova GS, Beaty T. 1993. Hereditary prostate cancer: epidemiologic and clinical features. J. Urol. 150:797-802
9. Zlotta AR, Schulman CC. 1999. Clinical evolution of prostatic intraepithelial neoplasia. Eur. Urol. 35:498-503
10. Klein EA, Meyskens FL. 2001. Potential target populations and clinical models for testing chemopreventative agents. Urology 57(Suppl. 1):171-73
11. Thompson IM, Goodman PJ, Tangen CM, et al. 2003. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349:215-24
12. Klein EA, Thompson M, Tangen CM, et al. 2005. Assessing benefit and risk in prevention of prostate cancer: the Prostate Cancer Prevention Trial revisited. J. Clin. Oncol. In press
13. Harlan SR, Cooperberg MR, Elkin EP, et al. 2003. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J. Urol. 170:1804-7
14. Civantos F, Soloway MS, Pinto JE. 1996. Histopathological effects of androgen deprivation in prostatic cancer. Semin. Urol. Oncol. 14:22-31
15. Unger JM, LeBlanc M, Thompson IM, et al. 2004. The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies. Urol. Oncol. 22:362-68
16. Lazier CB, Thomas LN, Douglas RC, et al. 2004. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate 58:130-44
17. Andriole GL, Roehrborn C, Schulman C, et al. 2004. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 64:537-41
18. Andriole G, Bostwick D, Brawley O, et al. 2004. Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J. Urol. 172:1314-17
19. Klein EA. 2004. Selenium-epidemiology and basic science. J. Urol. 11:S50-53
20. Vogt TM, Ziegler RG, Graubard BI, et al. 2003. Serum Se and risk of prostate cancer in U.S. blacks and whites. Int. J. Cancer 103:664-70
21. Clark LC, Combs GF Jr., Turnbull BW, et al. 1996. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276:1957-63
22. Duffield-Lillico AJ, Dalkin BL, Reid ME, et al. 2003. Se supplementation, baseline plasma Se status, and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Study Group. Br. J. Urol. Intl. 91:608-12
23. Ni J, Chen M, Zhang Y, et al. 2003. Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery. Biochem. Biophys. Res. Commun. 300:357-63
24. Thompson TA, Wilding G. 2003. Androgen antagonist activity by the antioxidant moiety of vitamin E, 2,2,5,7, 8-pentamethyl-6-chromanol in human prostate carcinoma cells. Mol. Cancer Ther. 2:797-803
25. Virtamo J, Pietinen P, Huttunen JK, et al. 2003. ATBC Study Group: incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA 290:476-85
26. Goodman GE, Schaffer S, Omenn GS, et al. 2003. The association between lung and prostate cancer risk, and serum micronutrients: results and lessons learned from Beta-Carotene and Retinol Efficacy Trial. Cancer Epidemiol. Biomarkers Prev. 12:518-26
27. Klein EA, Thompson IM, Lippman SM, et al. 2003. The Selenium and Vitamin E Cancer Prevention Trial. World J. Urol. 21:21-27
28. Peehl DM, Krishnan AV, Feldman D. 2003. Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J. Nutr. 133:24618-698
29. Bodiwala D, Luscombe CJ, French ME, et al. 2003. Susceptibility to prostate cancer: studies on interactions between UVR exposure and skin type. Carcinogenesis 24:711-17
30. Rodriguez C, McCullough ML, Mondul AM, et al. 2003. Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men. Cancer Epidemiol. Biomarkers Prev. 12:597-603
31. Krishnan AV, Peehl DM, Feldman D. 2003. Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression. J. Cell. Biochem. 88:363-71
32. Pruthi RS, Derksen E, Gaston K. 2003. Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. J. Urol. 169:2352-59
33. Hussain T, Gupta S, Mukhtar H. 2003. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett. 191:125-35
34. Pan Y, Zhang JS, Gazi MH, et al. 2003. The cyclooxygenase 2-specific non-steroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun in prostate cancer cells. Cancer Epidemiol. Biomarkers Prev. 12:769-74
35. Shappell SB, Olson SJ, Hannah SE, et al. 2003. Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma. Cancer Res. 63:2256-67
36. Steiner MS, Raghow S. 2003. Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk. World J. Urol. 21:31-36
37. Denis L, Morton MS, Griffith K. 1999. Diet and its preventive role in prostatic disease. Eur. Urol. 35:377-87
38. Raghow S, Hooshdaran MZ, Katiyar S, et al. 2002. Toremifine prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res. 62:1370-76
39. Klein EA. 2004. Prostate cancer. In Clinical Preventive Medicine, ed. RS Lang, DD Hansrud, pp. 120-35. Chicago: Am. Med. Assoc. 2nd ed.
40. Hedlund TE, Johannes WU, Miller GJ. 2003. Soy isoflavonoid equol modulates the growth of benign and malignant prostatic epithelial cells in vitro. Prostate 54:68-78
41. Cohen LA, Zhao Z, Pittman B, et al. 2003. Effect of soy protein isolate and conjugated linoleic acid on the growth of Dunning R-3327-AT-1 rat prostate tumors. Prostate 54:169-68
42. Yu L, Blackburn GL, Zhou JR. 2003. Genistein and daidzein downregulate prostate androgen-regulated transcript-1 (PART-1) gene expression induced by dihydrotestosterone in human prostate LNCaP cancer cells. J. Nutr. 133:389-92
43. Severson KJ, Nomura AMY, Grove JS, et al. 1989. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res. 49:1857-60
44. Adlercreutz H, Honjo H, Higashi A, et al. 1991. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am. J. Clin. Nutr. 54:1093-100
45. Hebert JR, Hurley TG, Olendzki BC, et al. 1998. Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J. Natl. Cancer Inst. 90:1637-47
46. Giovannucci E, Clinton SK. 1999. Tomatoes, lycopene, and cancer: review of the epidemiologic literature. J. Natl. Cancer Inst. 91:317-31
47. Obermuller-Jevic UC, Olano-Martin E. 2003. Lycopene inhibits the growth of normal human prostate epithelial cells in vitro. J. Nutr. 133:3356-60
48. Boileau TW, Liao Z, Kim S, et al. 2003. Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. J. Natl. Cancer Inst. 95:1578-86
49. Kucuk O, Sarkar FH, Sakr W, et al. 2001. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol. Biomarkers Prev. 10:861-68
50. Chen L, Stacewicz-Sapuntzakis M, Duncan C, et al. 2001. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J. Natl. Cancer Inst. 93:1872-79
51. Adhami VM, Ahmad N, Mukhtar H. 2003. Molecular targets for green tea in prostate cancer prevention. J. Nutr. 133(Suppl.):2417S-2424S
52. Hastak K, Gupta S, Ahmad N, et al. 2003. Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 22:4851-59
53. Brusselmans K, De Schrijver E, Heyns W, et al. 2003. Epigallocatechin-3- gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells. Int. J. Cancer 106:856-62